Position in CUE
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,478
-$7,120 QoQ
Shares Held
504
+2.6% QoQ
Ownership
0.007%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2022
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CUE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026XTX Topco Ltd holds $413,183,716 across 381 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
30,522 | $19,031,687 | |
| 2 | ASND |
Ascendis Pharma A/S
|
43,289 | $11,546,042 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
116,611 | $8,685,187 | |
| 4 | MRNA |
Moderna, Inc.
|
123,281 | $8,633,368 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
30,496 | $7,348,621 | |
| 6 | KYMR |
Kymera Therapeutics, Inc.
|
61,501 | $7,052,319 | |
| 7 | CYTK |
Cytokinetics Inc
|
80,743 | $6,878,496 | |
| 8 | PTCT |
Ptc Therapeutics, Inc.
|
81,923 | $6,682,459 |
All Filings in CUE
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,478 | 15,124 | Shares | Defined | 2026-05-15 | |
| 2025-09-30 | $10,598 | 14,741 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $15,340 | 22,493 | Shares | Defined | 2025-08-12 | |
| 2025-03-31 | $24,545 | 26,944 | Shares | Defined | 2025-05-08 | |
| 2024-12-31 | $51,200 | 46,973 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $20,942 | 27,665 | Shares | Defined | 2024-11-14 | |
| 2023-12-31 | $40,402 | 15,304 | Shares | Defined | 2024-02-13 | |
| 2023-09-30 | $122,520 | 53,270 | Shares | Defined | 2023-11-13 | |
| 2022-09-30 | $61,211 | 27,449 | Shares | Defined | 2022-11-14 | |
| 2022-06-30 | $96,719 | 38,843 | Shares | Defined | 2022-08-15 | |
| 2022-03-31 | $172,259 | 35,299 | Shares | Defined | 2022-05-13 | |
| No filing history on record for this holder in this stock. | ||||||